It has been widely reported that the number of highly complex and potent molecules entering development is rising, particularly in lieu of the fact that the bio/pharma industry is leaning towards personalized therapeutic offerings and drug development for orphan diseases.
Pharmaceutical Technology Europe caught up with JoyL Silva, General Manager of Pfizer CentreOne regarding the trends in the contract development and manufacturing organization (CDMO) sector working with complex molecules and the benefits of the embedded model.
